Treatment of dermal ulcer with autologous fibrin glue: Two case reports of an exploratory prospective pilot study
Rattachement africain : jp. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
INTRODUCTION: The healing of recurrent and refractory skin ulcers requires a long time, during which there is risk of infection, and hospital admission is occasionally required for surgical or daily conservative treatment. Therefore, the development of promising treatments that promote faster, uneventful healing is a must. Composed of cryoprecipitate and thrombin, fibrin glue has a history of surgical use for preventing bleeding and spinal fluid leakage. Moreover, in-house cryoprecipitates contain higher concentrations of coagulation factors and cytokines that may enhance wound healing than commercially available products. However, the efficacy of completely autologous fibrin glue (AFG) in tissue repair has not yet been fully demonstrated. PATIENT CONCERNS: This study aimed to evaluate the efficacy of AFG in the treatment of refractory skin ulcers in comparison with the conventional treatment. DIAGNOSIS: Two patients with skin ulcer on their lower extremities due to trauma or scleroderma who showed resistance to conventional treatment were included in the study. Both study participants were diagnosed with refractory skin ulcer and were ineligible for autologous skin transplantation. INTERVENTIONS: AFG was prepared following autologous blood donation using a Cryoseal® system. Subsequently, AFG was administered to 50% of the area of each ulcer and observed for 4 weeks in comparison with recombinant basic fibroblast growth factor with bucladesine sodium treatment that was administered to the rest of the ulcer. OUTCOMES: The skin ulcer after trauma in participant 1 showed better improvement in the AFG-treated area. Although AFG did not show superiority regarding the ulcer area of a patient with scleroderma, it guarded the continuous exudation from the edge of the swollen skin surrounding the ulcer. CONCLUSION: AFG showed effective and beneficial results for wound healing of refractory skin ulcer and prevented exudation without any severe adverse events.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Treatment of dermal ulcer with autologous fibrin glue: Two case reports of an exploratory prospective pilot study
- Date Crossref
- 17/11/2023
- Éditeur
- Ovid Technologies (Wolters Kluwer Health)
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Kobe University Hospital Department of Transfusion Medicine and Cell Therapy pays non établi dans la noticeÉtablissement de santé
-
Hyogo Prefectural Cancer Center pays non établi dans la noticeÉtablissement de santé
-
Kobe University Department of Medical Devices pays non établi dans la noticeUniversité ou école supérieure
-
102:46(e36134) pays non établi dans la noticeInstitution
-
How to cite this article: Kawamoto S pays non établi dans la noticeInstitution
-
Supplemental Digital Content is available for this article pays non établi dans la noticeInstitution
-
Department of Dermatology pays non établi dans la noticeInstitution
Department of Transfusion Medicine and Cell Therapy — Kobe University Hospital, Hyogo Prefectural Cancer Center et Department of Medical Devices — Kobe University, avec 4 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.